Changsha, China – 09 Sep 2026 – The Hunan Provincial Healthcare Security Administration (Hunan Medical Insurance Bureau) has issued a formal notice (Xiang Yi Bao Han [2026] No. 37) to implement the selection results of the nationally organized second‑round continuation volume‑based procurement (VBP) of coronary stent medical consumables, mandating that all public medical institutions in the province – including military hospitals – purchase and use selected products at the awarded prices from 1 October 2026, with the procurement cycle running through 30 June 2029.

Regulatory Milestone

Item	Detail
Issuing Agency	Hunan Provincial Healthcare Security Administration
Document	Xiang Yi Bao Han [2026] No. 37 (issued 9 Sep 2026)
Policy Type	Provincial implementation of national VBP second‑round continuation selection results
Product Scope	Coronary stent consumables – selected products per the attached national list
Effective Date	1 October 2026 (province‑wide unified execution)
Procurement Cycle	Through 30 June 2029; first contract year covers 1 Oct 2026 – 31 Dec 2027; agreements signed annually
Key Deadlines	Supplier registration & distribution setup on the Hunan Medical Procurement Platform by 30 Sep 2026; tripartite purchase‑sale agreements signed by 1 Nov 2026

Procurement Mechanism & Compliance Requirements

• Participating Institutions: All public medical institutions (including military facilities) and all institutions that reported volumes are required to purchase and use selected products; other medical‑insurance‑contracted institutions are encouraged to participate.
• Agreed Volumes: Annual contracted volumes are the quantities confirmed by hospitals in the procurement system (communicated separately to hospitals and winning suppliers). The first‑year volume is scaled at 15/12 of the annual agreement (rounded), reflecting the 15‑month initial contract period; non‑integer results are rounded.
• Beyond‑Agreement Supply: Purchases exceeding the agreed volume must still be supplied by winning companies at the selected price until the end of the procurement cycle.
• Platform‑Only Trading: All transactions must run through the Hunan Medical Procurement Platform; offline procurement, secondary price negotiation and any form of discount are strictly prohibited.
• Usage Floor: Selected products must account for no less than 80% of total same‑category procurement and usage volume during the agreement period; hospitals may buy other price‑appropriate products only after fulfilling contracted volumes.
• No Hidden Fees: Hospitals (including third‑party service providers) may not charge any additional fees for market entry, inventory or clinical use of selected stents, and may not block access citing cost control, product‑count limits, unreported volumes, quality deposits or distributor account caps.
• Supply Responsibility: Winning companies are the first‑line responsible party for quality and supply, and must maintain emergency stockpiles and report capacity shortfalls to the provincial bureau in advance; prior distribution relationships are automatically cleared upon implementation. Non‑compliance (supply failure, quality defects) will be escalated to the Joint Procurement Office, with penalties, disqualification and credit‑system consequences applied.

Price Guardrails – Red/Yellow Label Monitoring

Under the “price‑procurement linkage” mechanism, non‑selected coronary stents listed on the platform at elevated prices will carry warning labels benchmarked to the highest selected price, with procurement risk alerts issued to hospitals:

Product Category	Yellow Label Threshold (≥1.8× highest selected price)	Red Label Threshold (≥2.5× highest selected price)
Non‑selected coronary drug‑eluting alloy stents	¥1,708 / unit	¥2,372 / unit
Non‑selected coronary drug‑eluting stainless‑steel stents	¥1,526 / unit	¥2,120 / unit

Selected‑product awarded prices and company‑level results were not disclosed in the provincial notice (referenced to the national attachment list).

Market Impact & Outlook

• Continuity Signal: The second‑round continuation locks the nationally pioneered coronary stent VBP framework in place through mid‑2029, extending price certainty for hospitals and winning manufacturers after the landmark first round that reset China’s stent market.
• Pressure on Non‑Selected Products: The explicit red/yellow label price ceilings (1.8× / 2.5× the top awarded price) effectively cap how long premium‑priced non‑selected stents can compete in Hunan, pushing hospitals toward selected products and squeezing margin room for out‑of‑award brands.
• Hospital Enforcement Teeth: Execution progress is subject to “monthly monitoring and annual evaluation,” and is written into medical‑insurance designated‑hospital agreement assessments; hospitals with serious lag, unfulfilled volumes or heavy use of high‑priced non‑selected products face contractual consequences.
• Supplier Reset: Automatic clearing of prior distribution relationships forces winning companies to rebuild logistics coverage within weeks of the notice, while distributor performance (order response, delivery) becomes a compliance exposure for manufacturers.
• National Alignment: The notice stipulates that any national policy adjustments during the cycle will be followed accordingly, keeping Hunan’s execution synchronized with the central healthcare security authority’s continuation‑procurement playbook.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding procurement execution timelines, contract volumes, supply arrangements and price‑monitoring enforcement for the coronary stent VBP continuation in Hunan Province. Actual outcomes may differ due to risks including national policy adjustments, supplier capacity and distribution readiness, hospital compliance dynamics, and quality or supply disruptions. Company‑level awarded prices and volumes are not disclosed in the provincial notice.-China Health Reform Pulse

Policy Source: http://ybj.hunan.gov.cn/ybj/first113541/firstF/f3113607/202609/t20260910_34061201.html